Search

Displaying results 1881 - 1890 of 10000 in total
  1. Drug

    AMT-101

    go.drugbank.com/drugs/DB18555
    Investigational

    AMT-101 is a recombinant human interleukin-10 fusion protein.

    Synonyms: Recombinant human interleukin-10 fusion protein
  2. Drug

    Capsicum

    go.drugbank.com/drugs/DB10897
    Approved

    Capsicum (Chili pepper) allergenic extract is used in allergenic testing.

    Mixtures: Salonpas pain relieving HOT-LProducts: ABC Lokale Schmerz‐Therapie Aktiv‐Pflaster 4,8 mg wirkstoffhaltiges Pflaster
  3. Drug

    IO-202

    go.drugbank.com/drugs/DB17548
    Investigational

    IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4).[A257276] It is being investigated in cancers.

  4. Drug

    Lysozyme

    go.drugbank.com/drugs/DB13260
    Investigational

    Mixtures: LYSOBACT 20 MG/10 MG PASTİL, 30 ADET, E-zyme B6 TrocheProducts: E-zyme Syrup, E-zyme Troche
  5. Drug

    Dihydroxyaluminum sodium carbonate

    go.drugbank.com/drugs/DB15825
    Investigational

    Products: KOMPENSAN 340 MG TABLET, 20 ADET, KOMPENSAN 340 MG TABLET, 24 ADET
  6. Drug

    INKP-102

    go.drugbank.com/drugs/DB05326
    Experimental

    INKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.

  7. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

    Mixtures: Relief and Nature Toothpast E Jasmine MintInternational brands: E-Capro
  8. Drug

    ISB 2001

    go.drugbank.com/drugs/DB18570
    Investigational

    ISB 2001 is a T cell-engaging antibody that targets BCMA, CD38, and CD3.

  9. Drug

    FAV-201

    go.drugbank.com/drugs/DB06130
    Experimental

    FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.

  10. Drug

    XMT-1001

    go.drugbank.com/drugs/DB06069
    Investigational

    XMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human tumor xenografts models … XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity.